Crossmark

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Crossref DOI link: https://doi.org/10.1186/s12943-022-01583-z

Published Online: 2022-06-10

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Berlak, Mareike https://orcid.org/0000-0003-4437-3477
Tucker, Elizabeth

Dorel, Mathurin

Winkler, Annika

McGearey, Aleixandria

Rodriguez-Fos, Elias

da Costa, Barbara Martins

Barker, Karen

Fyle, Elicia

Calton, Elizabeth

Eising, Selma

Ober, Kim

Hughes, Deborah

Koutroumanidou, Eleni

Carter, Paul

Stankunaite, Reda

Proszek, Paula

Jain, Neha

Rosswog, Carolina

Dorado-Garcia, Heathcliff

Molenaar, Jan Jasper

Hubank, Mike

Barone, Giuseppe

Anderson, John

Lang, Peter

Deubzer, Hedwig Elisabeth

Künkele, Annette

Fischer, Matthias

Eggert, Angelika

Kloft, Charlotte

Henssen, Anton George

Boettcher, Michael

Hertwig, Falk

Blüthgen, Nils

Chesler, Louis

Schulte, Johannes Hubertus https://orcid.org/0000-0003-0671-1201
Funding

Funding for this research was provided by:

German Cancer Consortium

Alexander von Humboldt-Stiftung

Deutsche Forschungsgemeinschaft (398299703)

H2020 European Research Council (949172)

Berlin School of Integrative Oncology

Innovative Medicines Initiative (116064-ITCC-P4-H2020-JTI-IMI2-2015-07)

BIH-Charité Advanced Clinician Scientist

National Institute for Health Research

Charité - Universitätsmedizin Berlin
License Information

Text and Data Mining valid from 2022-06-10

Version of Record valid from 2022-06-10
More Information

Article History

Received: 9 January 2022

Accepted: 22 April 2022

First Online: 10 June 2022

Declarations

:

: Patients from Berlin, Germany were 22 months (patient 1, female) and 3 months old (patient 2, male) at diagnosis. The patient from London, UK was 26 months old (patient 3, female) and the patient from Cologne, Germany (patient 4, male) was 14 months old at diagnosis. For further information see Fig. A. German patients had been enrolled in the German Neuroblastoma Registry (NB Registry 2016) (). Written informed consent from patients or parents/guardians were obtained within the registry, ethics approval (16–432) was obtained from the ethics committee of the university hospital cologne. The GOSH patient was included in two research studies that had full UK research ethics approval and participated following informed consenting. Study one “Liquid biopsy study” was used for initial detection of mutations in plasma samples; study two “Strategic Medicine-Paediatrics” sequences tumour samples at time of relapse.All in vivo experimental protocols were monitored and approved by the ICR Animal Welfare and Ethical Review Body, in compliance with guidelines specified by the UK Home Office Animals (Scientific procedures) Act 1986 and the United Kingdom National Cancer Research Institute Guidelines for the Welfare of Animals in Cancer Research [].

: We obtained consent for publication of each patient parents or legal guardian.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below